Lakewood-Amedex CMO discloses share and option stake
Lakewood-Amedex Biotherapeutics Inc. Chief Medical Officer Thomas Balzer filed an initial ownership report describing his equity stake in the company.
Rhea-AI Filing Summary
Lakewood-Amedex Biotherapeutics Inc. Chief Medical Officer Thomas Balzer filed an initial ownership report describing his equity stake in the company. He directly holds 255,322 shares of common stock.
He also holds several stock options: rights to buy 168,919 shares of common stock at an exercise price of $2.31 per share expiring on July 1, 2035, and options to buy 46,115, 33,784, and 50,676 shares at an exercise price of $2.13 per share, expiring on March 13, 2034, March 1, 2033, and November 13, 2032, respectively. The filing records these positions as holdings rather than new purchases or sales.
Positive
- None.
Negative
- None.
Insider Trade Summary
5 transactions reported
Mixed
5 txns
Insider
Balzer Thomas
Role
Chief Medical Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Option (right to buy) | -- | -- | -- |
| holding | Common Stock; $0.0001 par value | -- | -- | -- |
Holdings After Transaction:
Option (right to buy) — 299,494 contracts (Direct);
Common Stock; $0.0001 par value — 255,322 shares (Direct)
Key Figures
Common stock held: 255,322 shares
Option at $2.31: 168,919 underlying shares
Option at $2.13 (2034): 46,115 underlying shares
+2 more
5 metrics
Common stock held
255,322 shares
Direct ownership reported on Form 3
Option at $2.31
168,919 underlying shares
Exercise price $2.31; expires July 1, 2035
Option at $2.13 (2034)
46,115 underlying shares
Exercise price $2.13; expires March 13, 2034
Option at $2.13 (2033)
33,784 underlying shares
Exercise price $2.13; expires March 1, 2033
Option at $2.13 (2032)
50,676 underlying shares
Exercise price $2.13; expires November 13, 2032
Key Terms
Form 3, Common Stock; $0.0001 par value, Option (right to buy, Chief Medical Officer
4 terms
Form 3 regulatory
"INSIDER FILING DATA (Form 3)"
Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.
Common Stock; $0.0001 par value financial
"security_title: "Common Stock; $0.0001 par value""
Option (right to buy financial
"security_title: "Option (right to buy)""
Chief Medical Officer financial
"officer_title: "Chief Medical Officer""
A chief medical officer is a senior executive responsible for overseeing the health and medical strategies within an organization, often in the healthcare or pharmaceutical sectors. They play a key role in guiding decisions related to medical research, product safety, and healthcare policies, which can impact a company's reputation and success. For investors, understanding the chief medical officer's role helps gauge how well a company manages medical risks and advances its healthcare goals.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does Lakewood-Amedex Biotherapeutics (LABT) Chief Medical Officer report in this Form 3?
The Form 3 shows Chief Medical Officer Thomas Balzer’s existing ownership in Lakewood-Amedex. He reports direct holdings of common stock plus several stock option positions, establishing a detailed baseline of his equity stake as an officer of the company.
What stock options are held by the Lakewood-Amedex (LABT) Chief Medical Officer?
He holds multiple options to buy Lakewood-Amedex common stock, including 168,919 shares at $2.31 per share and additional grants of 46,115, 33,784, and 50,676 shares at $2.13 per share, each with stated future expiration dates extending through 2035.
Are there any buy or sell transactions reported for LABT’s Chief Medical Officer in this Form 3?
The Form 3 records Balzer’s positions as holdings, not as new purchases or sales. All entries are classified as holdings with unknown transaction codes, indicating the filing primarily establishes his current ownership rather than reporting recent trading activity.
What are the expiration dates of Thomas Balzer’s Lakewood-Amedex (LABT) stock options?
His options expire on several dates: November 13, 2032; March 1, 2033; March 13, 2034; and July 1, 2035. Each option grant has its own expiration, defining how long he may exercise the right to buy the underlying LABT common shares.
What are the exercise prices on the Lakewood-Amedex (LABT) options held by the Chief Medical Officer?
The reported options have exercise prices of $2.31 and $2.13 per share. One grant covers 168,919 shares at $2.31, while three grants cover 46,115, 33,784, and 50,676 shares at $2.13, outlining the cost to convert each option into common stock.
AI-generated analysis. How Rhea-AI works. Not financial advice.
